Clinitech Laboratory Ltd vs Earkart Limited Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Clinitech Laboratory Ltd is ₹ 32 as of 07 Oct 15:30 . The P/E Ratio of Clinitech Laboratory Ltd is 23.3 as of March 2025 .The P/E Ratio of Earkart Limited is 0 as of March 2025 . The Market Cap of Clinitech Laboratory Ltd is ₹ 9.18 crore as of March 2025 .The Market Cap of Earkart Limited is ₹ 0 crore as of March 2025 . The Dividend Payout of Clinitech Laboratory Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Earkart Limited changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Clinitech Laboratory Ltd

Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 with the Registrar of Companies, Mumbai.
The status of Company was changed to Public Limited and the name of Company changed to Clinitech Laboratory Limited through fresh certificate of incorporation upon conversion on August 25, 2023 was issued by the Registrar of Companies, Mumbai.
Company is in the business of healthcare services providing superior quality services such as pathology testing laboratories, diagnostic centers, scan centers, X-ray and ECG clinics, etc. The Company established a new Lab in Kalyan in 2012, NABL Accreditation at Airoli Centre in 2016, a new Lab at Thane in 2018.
Besides these, the Company conduct more than 150 tests including Biochemistry, Immunology, Hematology, Molecular Biology tests, urine analysis, Serology, Microbiology and Histopathology tests.

About Earkart Limited

Earkart Limited was originally formed as a Private Limited Company in the name and style of 'Earkart Private Limited' on April 14, 2021 vide Certificate of Incorporation issued by Registrar of Companies, Kanpur.
On October 11, 2021, Rohit Misra acquired a majority of the equity shares from them and became the Promoter of the Company.
Thereafter, the status of the Company was taken public and the name was changed to 'Earkart Limited' dated December 18, 2024 by the Registrar of Companies, Central Processing Centre. Company manufacture and distribute modern hearing aids and related accessories at affordable price across India.
Along with the own manufactured hearing aid, it also trade in hearing aid, parts and accessories of other brands manufactured in India and abroad.
In addition, it offer other products like adjustable foldable walkers and MultiSensory Integrated Educational Development (MSIED) and Teaching Learning Material (TLM) kits to support mobility and daily needs of physically challenged.

FAQs for the comparison of Clinitech Laboratory Ltd and Earkart Limited

Which company has a larger market capitalization, Clinitech Laboratory Ltd or Earkart Limited?

Market cap of Clinitech Laboratory Ltd is 7 Cr while Market cap of Earkart Limited is 163 Cr

What are the key factors driving the stock performance of Clinitech Laboratory Ltd and Earkart Limited?

The stock performance of Clinitech Laboratory Ltd and Earkart Limited is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Clinitech Laboratory Ltd and Earkart Limited?

As of October 25, 2026, the Clinitech Laboratory Ltd stock price is INR ₹32.0. On the other hand, Earkart Limited stock price is INR ₹119.1.

How do dividend payouts of Clinitech Laboratory Ltd and Earkart Limited compare?

To compare the dividend payouts of Clinitech Laboratory Ltd and Earkart Limited, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.